Alessandro Gronchi, MD, discusses the results of the phase 2 TRASTS trial in soft tissue sarcoma.
Alessandro Gronchi, MD
Advertisement
Articles by Alessandro Gronchi, MD
Alessandro Gronchi, MD, discusses the toxicity profile of trabectedin and radiation therapy in patients with soft tissue sarcoma.
Alessandro Gronchi, MD, discusses the rationale for the phase 2 TRASTS study in soft tissue sarcoma.
Advertisement
Latest Updated Articles
Dr. Gronchi on the Results of the TRASTS Trial in Soft Tissue SarcomaPublished: October 23rd 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5